Rapid and Multiplex Diagnosis of Malaria Using Chelex-100 Extraction and LAMP-MS Assay

Materials and reagents

Biological materials

Malaria residual blood samples were collected from patients suspected of malaria infection at Korea University Guro Hospital between 2013 and 2022. Whole blood samples were collected from patients using standard venipuncture techniques into EDTA-containing tubes, gently mixed, and stored at 4 °C until further processing. After routine diagnostic testing, they were stored at -80 °C. Malaria infection was confirmed through various methods, including Giemsa staining, blood smear microscopy, rapid antigen tests, and PCR tests. Procedures involving clinical samples, including handling and nucleic acid extraction, were conducted under Biosafety Level 2 (BSL-2) conditions. This study was approved by the Medical Ethics Committee of Korea University’s Guro Hospital (2021GR0337).

1. 80 P. falciparum clinical samples

2. 80 P. vivax clinical samples

3. 100 negative clinical samples

4. Zika virus, Chikungunya virus, and Japanese encephalitis virus, provided by the Korea Disease Control and Prevention Agency (KDCA)

Reagents

1. Chelex-100 resin (Bio-Rad, catalog number: 142-1253)

2. Tris-EDTA buffer solution (Sigma-Aldrich, catalog number: T9285)

3. Phosphate-buffered saline (PBS) (Thermo Fisher Scientific, catalog number: 10010-023)

Solutions

1. LAMP primer mix (see Recipes)

Recipes

1. LAMP primer mix

a. Prepare primer solutions separately for each target (Pan, Pf, Pv, IC) at the following final concentrations:

i. 4 μM of each outer primer (F3 and B3)

ii. 32 μM of each inner primer (FIP and BIP)

iii. 10 μM of each loop primer (FLP and BLP)

b. Each primer set solution (Pan, Pf, Pv, IC) is prepared from 100 μM stock solutions by mixing 4 μL each of F3 and B3, 32 μL each of FIP and BIP, and 10 μL each of FLP and BLP, followed by the addition of 18 μL of nuclease-free water (Table 1).

Table 1. Multi-malaria pan/Pf/Pv/IC LAMP-MS primer sets used in this study

Target	Name	Sequence (5′-3′)	Length (mer)
Malaria pan (18S rRNA gene)	Malaria pan F3	GTA TCA ATC GAG TTT CTG ACC	21
	Malaria pan B3	CTT GTC ACT ACC TCT CTT CT	20
	Malaria pan FIP	TCG AAC TCT AAT TCC CCG TTA CCT ATC AGC TTT TGA TGT TAG GGT	45
	Malaria pan BIP	CGG AGA GGG AGC CTG AGA AAT AGA ATT GGG TAA TTT ACG CG	41
	Malaria pan FLP	CGT CAT AGC CAT GTT AGG CC	20
	Malaria pan BLP	AGC TAC CAC ATC TAA GGA AGG CAG	24
Plasmodium falciparum (LDH gene)	P. falciparum F3	AAT TGT AAA CTT ACA TGC ATC AC	23
	P. falciparum B3	TCA AAT TTA GCT TTT TCC TCA CT	23
	P. falciparum FIP	GCC CTT CTA ACA AGG TTG AGC AGC TGC TGC TAT TAT CGA AAT	42
	P. falciparum BIP	TAT GGA CAC TCC GAT ATA TTC GGT GTA ATT CGA TAA CTT GTT CAA CAC	48
	P. falciparum FLP	CAA ATC TTT AAG TAG GAT TCA GCC	24
	P. falciparum BLP	GGT ACA CCT GTT GTT TTA GGT GCT	24
Plasmodium vivax (16S rRNA gene)	P. vivax F3	GGA ATG ATG GGA ATT TAA AAC CT	23
	P. vivax B3	ACG AAG TAT CAG TTA TGT GGA T	22
	P. vivax FIP	CTA TTG GAG CTG GAA TTA CCG CTC CCA AAA CTC AAT TGG AGG	42
	P. vivax BIP	AAT TGT TGC AGT TAA AAC GCT CGT AAG CTA GAA GCG TTG CT	41
	P. vivax FLP	GCT GCT GGC ACC AGA CTT	18
	P. vivax BLP	AGT TGA ATT TCA AAG AAT CG	20
Human (actin gene)	IC F3	AGT ACC CCA TCG AGC ACG	18
	IC B3	AGC CTG GAT AGC AAC GTA CA	20
	IC FIP	GAG CCA CAC GCA GCT CAT TGT ATC ACC AAC TGG GAC GAC A	40
	IC BIP	CTG AAC CCC AAG GCC AAC CGG CTG GGG TGT TGA AGG TC	38
	IC FLP	TGT GGT GCC AGA TTT TCT CCA	21
	IC BLP	CGA GAA GAT GAC CCA GAT CAT GT	23

Laboratory supplies

1. 1.5 mL microcentrifuge tubes (Axygen, catalog number: MCT-150-C)

2. Mmiso^® DNA Amplification kit master mix (Mmonitor, catalog number: 22202)

3. DNA extraction tube set (Biozentech, catalog number: NAE-03)

4. 4-chambers grid microchip (Biozentech, catalog number: BZC-04G)

5. Sealing tape (Bio-Rad, catalog number: MSB1001)

6. Aluminum foil (Taeshin Bioscience, catalog number: TS-TF3050)

Equipment

1. Micropipettes 0.1–2.5 μL, 2–20 μL, 20–200 μL (Eppendorf, catalog numbers: 3123000012, 3123000098, 3123000039)

2. Aptical RV400TMCL microscope (OMAX OMB microscope, Gyeonggi-do, Korea; field-deployable with built-in battery and monitor)

3. Microscanner (OMAX, model: RV400TMCL)

4. Vortex-Genie^® 2 (Scientific Industries, catalog number: SI-0246A)

5. Heat block (BioFree, catalog number: BF-40HB)

6. Complete blood count (CBC) analyzer (Beckman Coulter, catalog number: B23858)

7. Incubator (L&T Co., catalog number: LT-201S)

8. Refrigerator (LG Electronics, catalog number: LG B607W)

Software and datasets

1. Diagnostic test calculator: https://www.medcalc.org/calc/diagnostic_test.php

Procedure

A. Preparation of 10% Chelex-100 solution

1. Weigh 1 g of Chelex-100 resin using an analytical balance and transfer to a sterile 15 mL conical tube.

2. Add 10 mL of TE buffer (see Recipes) to the tube containing the resin.

3. Vortex vigorously for 1 min until the resin is uniformly suspended.

4. Dispense 195 μL aliquots into DNA extraction tubes (Figure 1) and store at 4 °C until use.

Figure 1. Workflow of Chelex-100/boiling extraction using a custom tube and its application to a four-chamber LAMP-MS chip. (A) Components of the Chelex-100/boiling nucleic acid extraction tube. (B) Assembly steps of the tube. (C) Step-by-step illustration of the nucleic acid extraction procedure using the assembled tube. (D) Layout of the four-chamber microchip used in the LAMP-MS assay, consisting of detection chambers for malaria pan, P. falciparum, P. vivax, and an internal control.

B. DNA extraction by Chelex-100/boiling method

1. Thaw frozen blood samples gently at room temperature and vortex briefly to mix.

2. Add exactly 5 μL of blood sample into the pre-filled extraction tube containing 195 μL of Chelex-100 suspension (Figure 1c)

3. Cap tubes tightly and vortex briefly to mix thoroughly.

4. Incubate tubes in a heating block set to 100 °C for exactly 10 min.

5. Immediately after incubation, gently press the tube to filter the heated sample through the built-in filter into a clean 1.5 mL microcentrifuge tube.

6. Collect approximately 100 μL of filtered DNA-containing solution and store immediately at -20 °C until further analysis.

Pause point: Extracted DNA can be stored at -20 °C for up to one month before the LAMP assay.

C. Microchip preparation

1. Pipette exactly 0.5 μL of each primer solution into each respective chamber of the four-chamber microchip (Figure 1d).

2. Dry loaded microchips at 60 °C in an incubator for precisely 1 h.

3. After drying, label the microchips with the preparation date and primer targets. Wrap them in aluminum foil and store at room temperature until use.

D. LAMP reaction setup

1. Prepare LAMP reaction mix for each sample as follows:

a. 25 μL of Mmiso master mix.

b. 4 μL of Mmiso enzyme.

c. 15 μL of distilled water.

d. 6 μL of extracted DNA (prepared and stored as described in step B7).

2. Vortex gently to homogenize the reaction mix.

3. Load exactly 10 μL of the prepared reaction mix into each chamber of the dried microchip, taking care to avoid bubble formation.

4. Seal microchip chambers with sealing tape carefully to prevent evaporation during incubation.

5. Place the microchip onto a heating block preheated and maintained accurately at 62 °C. Incubate for exactly 30 min.

E. Result interpretation

1. After incubation, immediately remove the microchip from the heating block.

2. Examine each chamber visually under a microscanner or optical microscope.

3. Positive reactions show clearly visible white granules, representing magnesium pyrophosphate, indicating successful amplification.

4. Negative reactions appear clear without visible granules.

5. Record results promptly and dispose of used microchips safely according to laboratory biosafety guidelines.

Data analysis

Visual results; statistical performance (sensitivity/specificity) analyzed via MedCalc (https://www.medcalc.org/calc/diagnostic_test.php).

Validation of protocol

A. Limit of detection (LoD)

1. Clinical whole blood samples confirmed to be positive for Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) were selected. Parasite densities in the original samples were estimated based on hospital patient records and microscopic examination of Giemsa-stained blood smears, in conjunction with white blood cell (WBC) counts.

2. Microscopic examination

a. Parasites (ring, trophozoite, and schizont) are counted against 100 WBCs, and the result is expressed as the number of parasites per microliter of blood, based on the actual WBC count obtained from a complete blood count (CBC) analyzer.

b. Calculation formula:

P a r a s i t e s / μ L = N u m b e r o f p a r a s i t e s c o u n t e d N u m b e r o f W B C s c o u n t e d × a c t u a l W B C c o u n t * ( p e r μ L )

The actual WBC count was obtained from hospital records or measured using a CBC analyzer.

3. Based on this analysis, the estimated parasite densities were determined to be:

a. P. falciparum: 114,511 parasites/μL

b. P. vivax: 20,832 parasites/μL

c. Each clinical sample was serially diluted 10-fold in PBS to generate a range of parasite concentrations. For P. falciparum, dilutions ranged from 1.1 × 10⁵ to 1.1 × 10^-1 parasites/μL, and for P. vivax, from 2 × 10⁴ to 2 × 10^-2 parasites/μL.

d. Genomic DNA was extracted from each dilution using the Chelex-100/boiling method.

4. Extracted DNA samples were tested using the malaria pan/Pf/Pv/IC LAMP-MS assay.

5. The limit of detection (LoD) test of the malaria pan/Pf/Pv/IC LAMP-MS assay was repeated in three independent experiments.

6. The LoD was defined as the lowest parasite concentration that yielded consistent positive results in all three replicates.

7. The LOD of the malaria pan/Pf/Pv/IC LAMP-MS assay was determined to be 1.1 × 10² parasites/μL for Plasmodium falciparum and 2 × 10² parasites/μL for Plasmodium vivax (Table 2, Figure 2).

Table 2. Limit of detection (LOD) tests of malaria pan/Pf/Pv/IC LAMP-MS assay using 10-fold serial diluted P. falciparum and P. vivax samples

Assay	Samples	Target	Parasites/μL
			1.1×105	1.1×104	1.1×103	1.1×102	1.1×101	1.1×100	1.1×10-1	DW
Malaria pan LAMP-MS (P/N)	P. falciparum	Pan	P	P	P	P	N	N	N	N
		Pf	P	P	P	P	N	N	N	N
		Pv	N	N	N	N	N	N	N	N
		IC	P	P	P	N	N	N	N	N
			2×104	2×103	2×102	2×101	2×100	2×10-1	2×10-2	DW
	P. vivax	Pan	P	P	P	N	N	N	N	N
		Pf	N	N	N	N	N	N	N	N
		Pv	P	P	P	N	N	N	N	N
		IC	P	P	P	N	N	N	N	N

P/N: positive/negative; N/A: not applicable.

Figure 2. Limit of detection (LOD) tests for the malaria pan/Pf/Pv/IC LAMP-MS assay using 10-fold serially diluted P. falciparum (left panel) and P. vivax (right panel) DNA samples extracted by the Chelex-100/boiling method

B. Clinical test

1. The clinical performance of the malaria pan/Pf/Pv/IC LAMP-MS assay was evaluated using a total of 260 clinical whole blood samples (Table 3, Figure 3), composed of:

a. 80 samples positive for Plasmodium falciparum (Pf)

b. 80 samples positive for Plasmodium vivax (Pv)

c. 100 non-infected (negative control) samples

Table 3. Sensitivity and specificity of malaria pan/Pf/Pv/IC LAMP-MS assay against P. falciparum, P. vivax, and non-infection clinical samples

Clinical samples		Malaria pan/Pf/Pv/IC LAMP-MS assay
		Pan	Pf	Pv	IC
P. falciparum (n = 80)	P/N	78/80	80/80	0/80	80/80
	Sensitivity [95% CI]	97.5% [91.3–99.7]	100% [95.5–100.0]	-	100% [95.5–100.0]
	Specificity [95% CI]	-	-	100% [95.5–100.0]	-
P. vivax (n = 80)	P/N	76/80	0/80	75/80	80/80
	Sensitivity [95% CI]	95% [87.7–98.2]	-	94% [86.0–97.9]	100% [95.5–100.0]
	Specificity [95% CI]	-	100% [95.5–100.0]	-	-
Non-infection (n = 100)	P/N	0/100	0/100	0/100	100/0
	Sensitivity [95% CI]	-	-	-	100% [96.4–100.0]
	Specificity [95% CI]	100% [96.4–100.0]	100% [96.4–100.0]	100% [96.4–100.0]	-

CI: confidence interval; P/N: positive/negative

Figure 3. Representative malaria pan/Pf/Pv/IC LAMP-MS assay results for clinical malaria samples. Microscopic images show the results of the LAMP-MS assay performed on clinical samples infected with Plasmodium falciparum and Plasmodium vivax and non-infected clinical samples. Four detection channels are shown: pan-malaria (Pan), P. falciparum-specific (Pf), P. vivax-specific (Pv), and internal control (IC). Amplified products appear as dense clustered signals, while negative results show clear backgrounds. Scale bars: 1 μm.

2. DNA was extracted from all samples using the Chelex-100/boiling DNA extraction method and subsequently analyzed using the LAMP-MS assay.

3. For P. falciparum samples:

a. Malaria pan/Pf/Pv/IC LAMP-MS assay showed a sensitivity of 97.5% for the pan target (95% CI: 91.3–99.7) and 100% for the Pf-specific target (95% CI: 95.5–100.0).

b. Malaria pan/Pf/Pv/IC LAMP-MS assay exhibited 100% specificity, with no false positives.

4. For P. vivax samples:

a. Malaria pan/Pf/Pv/IC LAMP-MS assay showed a sensitivity of 95.0% for the pan target (95% CI: 87.7–98.2) and 94.0% for the Pv-specific target (95% CI: 86.0–97.9).

b. Malaria pan/Pf/Pv/IC LAMP-MS assay demonstrated 100% specificity, with no false positives.

5. For the 100 non-infected samples:

• Malaria pan/Pf/Pv/IC LAMP-MS assay achieved 100% specificity across all diagnostic targets (pan, Pf, Pv) with no false positives.

• Internal control (IC) was detected in 100% of the samples, confirming sample integrity and reaction validity.

C. Cross-reactivity

1. To evaluate the specificity of the malaria pan/Pf/Pv/IC LAMP-MS assay, potential cross-reactivity was assessed using RNA or DNA from clinical samples infected with non-malarial pathogens.

2. The assay was tested against the following viruses: Zika virus (ZIKV), Chikungunya virus (CHIKV), Japanese encephalitis virus (JEV), and Dengue virus (DENV), including all four serotypes (DENV-1, DENV-2, DENV-3, DENV-4).

3. Additional negative control tests were conducted using human whole blood genomic DNA (malaria-negative donors) and distilled water (no-template control).

4. Each sample was subjected to the standard LAMP-MS protocol, and amplification was evaluated across all diagnostic targets: Pan, Plasmodium falciparum (Pf), Plasmodium vivax (Pv), and internal control (IC).

5. The LAMP-MS assay produced negative results for all malaria targets (Pan, Pf, Pv) and the internal control (IC) in all non-malarial viral samples. In contrast, the assay yielded positive results only for the internal control (IC) when tested with human whole blood DNA, confirming assay validity and high specificity (Table 4).

Table 4. Cross-reactivity of the malaria pan/Pf/Pv/IC LAMP-MS assay against other virus infection samples

Samples	Malaria pan/Pf/Pv/IC LAMP-MS assay
	Pan	Pf	Pv	IC
Zika virus	N	N	N	N
Dengue 1 virus	N	N	N	N
Dengue 2 virus	N	N	N	N
Dengue 3 virus	N	N	N	N
Dengue 4virus	N	N	N	N
Chikungunya virus	N	N	N	N
Japanese encephalitis	N	N	N	N
Human whole blood DNA	N	N	N	P
Distilled water	N	N	N	N

P/N: positive/negative

This protocol or parts of it has been used and validated in the following research article(s):

• Jang et al. [12]. Development of a rapid malaria LAMP-MS assay for diagnosis of malaria infections. Scientific Reports (Figure 3B).

General notes and troubleshooting

1. To prevent cross-contamination during chip loading, use filtered pipette tips and change tips between samples. Cross-contamination can lead to false-positive results, especially in isothermal amplification assays [13].

2. Air bubbles introduced during pipetting can inhibit LAMP reactions by disrupting uniform thermal distribution and reagent mixing, potentially leading to false-negative or inconsistent results. To minimize bubble formation, we recommend pipetting slowly using low-retention tips and taking care to avoid introducing air into the reaction mixture during reagent loading. In addition, Mahdavi et al. [14] reported that centrifugal microfluidic chips effectively eliminate bubbles and residual volumes, contributing to more stable amplification.

3. This method is recommended for use in resource-limited or field settings due to its simplicity and minimal equipment requirements. However, full integration into automated high-throughput systems may be limited. To enable full field applicability of the assay, development of a battery-operated heat block would be necessary.

Acknowledgments

This work was supported by a grant from the Korea Health Technology R&D Project, through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HR20C0021); a grant from the National Research Foundation of Korea (NRF), funded by the Korean Government, MSIP (RS-2023-00207833); and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number: 2022R1I1A1A01063976). This protocol was used in [12].

Competing interests

The authors declare no competing interests.

Ethical considerations

This study was approved by the Medical Ethics Committee of Korea University’s Guro Hospital (2021GR0337).

References

1. Paton, D. G., Childs, L. M., Itoe, M. A., Holmdahl, I. E., Buckee, C. O. and Catteruccia, F. (2019). Exposing Anopheles mosquitoes to antimalarials blocks Plasmodium parasite transmission. Nature. 567(7747): 239–243. https://doi.org/10.1038/s41586-019-0973-1
2. Rosenthal, P. J. (2022). Malaria in 2022: Challenges and Progress. Am J Trop Med Hyg. 106(6): 1565–1567. https://doi.org/10.4269/ajtmh.22-0128
3. Roberts, D. and Matthews, G. (2016). Risk factors of malaria in children under the age of five years old in Uganda. Malar J. 15: 246. https://doi.org/10.1186/s12936-016-1290-x
4. Landier, J., Parker, D. M., Thu, A. M., Carrara, V. I., Lwin, K. M., Bonnington, C. A., Pukrittayakamee, S., Delmas, G. and Nosten, F. H. (2016). The role of early detection and treatment in malaria elimination. Malar J. 15: 363. https://doi.org/10.1186/s12936-016-1399-y
5. Yoon, J., Jang, W. S., Nam, J., Mihn, D. C. and Lim, C. S. (2021). An Automated Microscopic Malaria Parasite Detection System Using Digital Image Analysis. Diagnostics. 11(3): 527. https://doi.org/10.3390/diagnostics11030527
6. Mouatcho, J. C. and Goldring, J. P. D. (2013). Malaria rapid diagnostic tests: challenges and prospects. J Med Microbiol. 62(Pt 10): 1491–1505. https://doi.org/10.1099/jmm.0.052506-0
7. Britton, S., Cheng, Q. and McCarthy, J. S. (2016). Novel molecular diagnostic tools for malaria elimination: a review of options from the point of view of high-throughput and applicability in resource limited settings. Malar J. 15: 88. https://doi.org/10.1186/s12936-016-1158-0
8. McMorrow, M. L., Aidoo, M. and Kachur, S. P. (2011). Malaria rapid diagnostic tests in elimination settings--can they find the last parasite? Clin Microbiol Infect. 17(11): 1624–1631. https://doi.org/10.1111/j.1469-0691.2011.03639.x
9. Lucchi, N. W., Ndiaye, D., Britton, S. and Udhayakumar, V. (2018). Expanding the malaria molecular diagnostic options: opportunities and challenges for loop-mediated isothermal amplification tests for malaria control and elimination. Expert Rev Mol Diagn. 18(2): 195–203. https://doi.org/10.1080/14737159.2018.1431529
10. Abdul-Ghani, R., Al-Mekhlafi, A. M. and Karanis, P. (2012). Loop-mediated isothermal amplification (LAMP) for malarial parasites of humans: would it come to clinical reality as a point-of-care test? Acta Trop. 122(3): 233–240. https://doi.org/10.1016/j.actatropica.2012.02.004
11. Cuadros, J., Pérez-Tanoira, R., Prieto-Pérez, L., Martin-Martin, I., Berzosa, P., González, V., Tisiano, G., Balcha, S., Ramos, J. M. and Górgolas, M. (2015). Field Evaluation of Malaria Microscopy, Rapid Malaria Tests and Loop-Mediated Isothermal Amplification in a Rural Hospital in South Western Ethiopia. PLoS One. 10(11): e0142842. https://doi.org/10.1371/journal.pone.0142842
12. Jang, W. S., Choi, M. K., Choe, Y. L. and Lim, C. S. (2025). Development of a rapid malaria LAMP-MS assay for diagnosis of malaria infections. Sci Rep. 15(1): 8547. https://doi.org/10.1038/s41598-025-92935-4
13. Shakeri, A., Yousefi, H., Abu Jarad, N., Kullab, S., Al-Mfarej, D., Rottman, M. and Didar, T. F. (2022). Contamination- and carryover-free handling of complex fluids using lubricant-infused pipette tips. Sci Rep. 12: 15002. https://doi.org/10.1038/s41598-022-18756-x
14. Mahdavi, F., Niyyati, M., Shamloo, A., Dezhkam, R., Hoseinian, S. M., Seyyedtabaei, S. J. and Mirjalali, H. (2025). Design and fabrication of multiplex microfluidic LAMP PCR for simultaneous detection of opportunistic protozoa. Sens Bio-Sens Res. 48: 100787. https://doi.org/10.1016/j.sbsr.2025.100787